1,009
Participants
Start Date
May 20, 2016
Primary Completion Date
October 24, 2020
Study Completion Date
October 24, 2020
sacubitril/valsartan
This study is designed as an observational, naturalistic, multicenter study in patients being treated with sacubitril/valsartan as per the Canadian product label. Treatment initiation with sacubitril/valsartan must be within the last 3 months. Sacubitril/valsartan will be used as commercially available supplies which are available as Film coated tablets in 3 dosage: 1) 24 mg sacubitril / 26 mg valsartan, 2) 49 mg sacubitril / 51 mg valsartan and 3) 97 mg sacubitril / 103 mg valsartan.
Novartis Investigative Site, Calgary
Novartis Investigative Site, Calgary
Novartis Investigative Site, Edmonton
Novartis Investigative Site, Maple Ridge
Novartis Investigative Site, North Vancouver
Novartis Investigative Site, Winnipeg
Novartis Investigative Site, Moncton
Novartis Investigative Site, Halifax
Novartis Investigative Site, Brampton
Novartis Investigative Site, Burlington
Novartis Investigative Site, Cambridge
Novartis Investigative Site, Greater Sudbury
Novartis Investigative Site, Newmarket
Novartis Investigative Site, Oakville
Novartis Investigative Site, Sarnia
Novartis Investigative Site, Scarborough Village
Novartis Investigative Site, Toronto
Novartis Investigative Site, Waterloo
Novartis Investigative Site, Weston
Novartis Investigative Site, Chicoutimi
Novartis Investigative Site, Greenfield Park
Novartis Investigative Site, Joliette
Novartis Investigative Site, Laval
Novartis Investigative Site, Lévis
Novartis Investigative Site, Montreal
Novartis Investigative Site, Montreal
Novartis Investigative Site, Québec
Novartis Investigative Site, Saint-Jean-sur-Richelieu
Novartis Investigative Site, Sainte-Foy
Novartis Investigative Site, Sherbrooke
Novartis Investigative Site, St-George
Novartis Investigative Site, Trois-Rivières
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY